High Altitude Pulmonary Hypertension, Oxygen Therapy
Conditions
Brief summary
To study whether oxygen therapy titrated to maintain oxygenation (SpO2) \> 90% at 2500m would resolve altitude-related adverse health effects, symptoms and impaired exercise during 30h exposure to high altitude.
Detailed description
Patients with pulmonary hypertension who reveal an altitude-related adverse health effects at 2500m will be given oxygen therapy by nasal cannula titrated to maintain the oxygen saturation above 90%. The study will investigate, whether this measure will restore altitude-induced impairment to baseline levels at low altitude.
Interventions
OTHEROxygen Therapy
Oxygen Therapy in patients developing an altitude related adverse health effect (ARAHE) during 30h exposure to 2500m of high altitude
Sponsors
University of Zurich
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Informed consent as documented by signature * PH class I (PAH) or IV (CTEPH) diagnosed according to guidelines: mean pulmonary artery pressure \>20 mmHg, pulmonary vascular resistance ≥3 wood units, pulmonary arterial wedge pressure ≤15 mmHg during baseline measures at the diagnostic right-heart catheterization
Exclusion criteria
* resting partial pressure of oxygen \<8 kilopascal at Zurich at 490 m low altitude * exposure to an altitude \>1000 m for ≥3 nights during the last 2 weeks before the study * inability to follow the procedures of the study * other clinically significant concomitant end-stage disease (e.g., renal failure, hepatic dysfunction)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recovery from ARAHE | 30 hours | Proportion of patients with precapillary pulmonary hypertension experiencing an ARAHE at 2500 m of high altitude and receiving oxygen therapy titrated to achieve SpO2 ≥ 90% who recover from ARAHE, have improved symptoms and achieve constant work-rate exercise time within a minimal important difference as defined for patients with respiratory disease within 1.75 min of baseline value at 490 m; time frame within 6 h after initiation of oxygen therapy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Maximum work-rate in incremental ramp cycle exercise tests | 30 hours | Difference with oxygen therapy at high altitude vs. low altitude in maximal exercise capacity during a incremental ramp cycle exercise test |
| Hemodynamics | 30 hours | Difference with oxygen therapy at high altitude vs. low altitude in hemodynamics assessed by echocardiography at rest including pulmonary artery pressure, cardiac output, pulmonary vascular resistance and right heart function assessed as tricuspid plane systolic excursion and fractional area change. |
| Borg dyspnoea scale | 30 hours | Difference with oxygen therapy at high altitude vs. low altitude baseline in post-exercise Borg dyspnoea scale going from 1-10 scores with higher values meaning worse dyspnea |
| Visual Analogue Scale | 30 hours | Difference with oxygen therapy at high altitude vs. low altitude baseline in symptoms assessed by the Visual Analogue Scale for dyspnoea, a 10cm line from left to right where patients have to add a cross-line with higher values meaning better feeling. |
| Constant work-rate exercise time | 30 hours | Difference with oxygen therapy at high altitude vs. low altitude in constant work-rate exercise time cycle exercise test at 75% Wmax at low altitude |
| sit-to-stand test | 30 hours | Difference with oxygen therapy at high altitude vs. low altitude baseline in sit-to-stand test |
| Sleep disordered breathing | 30 hours | Difference with oxygen therapy at high altitude vs. low altitude in sleep disordered breathing |
| 6 minute walk test | 30 hours | Difference with oxygen therapy at high altitude vs. low altitude in 6 minute walk test |
| Acute Mountain Sickness Score | 30 hours | Difference with oxygen therapy at high altitude vs. low altitude baseline in symptoms assessed by the Lake Louise acute mountain sickness score going from 0-12 points with mild AMS as 3-5 points, moderate AMS as 6-9 points, and severe AMS as 10-12 points. |
| Cognitive testing | 30 hours | Difference with oxygen therapy at high altitude vs. low altitude baseline in cognitive function tests |
Countries
Switzerland
Outcome results
None listed